TY - JOUR
T1 - The potential of mesenchymal stromal cells in neuroblastoma therapy for delivery of anti-cancer agents and hematopoietic recovery
AU - Hochheuser, Caroline
AU - Kunze, Nina Y.
AU - Tytgat, Godelieve A.M.
AU - Voermans, Carlijn
AU - Timmerman, Ilse
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3
Y1 - 2021/3
N2 - Neuroblastoma is one of the most common pediatric cancers and a major cause of cancerrelated death in infancy. Conventional therapies including high-dose chemotherapy, stem cell transplantation, and immunotherapy approach a limit in the treatment of high-risk neuroblastoma and prevention of relapse. In the last two decades, research unraveled a potential use of mesenchymal stromal cells in tumor therapy, as tumor-selective delivery vehicles for therapeutic compounds and oncolytic viruses and by means of supporting hematopoietic stem cell transplantation. Based on pre-clinical and clinical advances in neuroblastoma and other malignancies, we assess both the strong potential and the associated risks of using mesenchymal stromal cells in the therapy for neuroblastoma. Furthermore, we examine feasibility and safety aspects and discuss future directions for harnessing the advantageous properties of mesenchymal stromal cells for the advancement of therapy success.
AB - Neuroblastoma is one of the most common pediatric cancers and a major cause of cancerrelated death in infancy. Conventional therapies including high-dose chemotherapy, stem cell transplantation, and immunotherapy approach a limit in the treatment of high-risk neuroblastoma and prevention of relapse. In the last two decades, research unraveled a potential use of mesenchymal stromal cells in tumor therapy, as tumor-selective delivery vehicles for therapeutic compounds and oncolytic viruses and by means of supporting hematopoietic stem cell transplantation. Based on pre-clinical and clinical advances in neuroblastoma and other malignancies, we assess both the strong potential and the associated risks of using mesenchymal stromal cells in the therapy for neuroblastoma. Furthermore, we examine feasibility and safety aspects and discuss future directions for harnessing the advantageous properties of mesenchymal stromal cells for the advancement of therapy success.
KW - Biodistribution
KW - Cellular therapy
KW - Drug delivery
KW - Hematopoietic stem cell transplantation
KW - Mesenchymal stem/stromal cells
KW - Neuroblastoma
KW - Oncolytic virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85102343373&partnerID=8YFLogxK
U2 - 10.3390/jpm11030161
DO - 10.3390/jpm11030161
M3 - Review article
AN - SCOPUS:85102343373
VL - 11
SP - 1
EP - 24
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
SN - 2075-4426
IS - 3
M1 - 161
ER -